| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) – |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
− Achieved Second Quarter 2026 Global Net Product Revenues of $1,172 Million (74% Growth Compared with Q2 2025), Driven Primarily by Total TTR Revenues of $1,030 Million (89% Growth Compared with Q2 2025) – |
| 27 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025) – |
| 04 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – |
| 11 Dec 2025 |
8-K: Other Events
CAMBRIDGE, Mass. — December 11, 2025 — Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with ce... |
| 03 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – |
| 03 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
Administrative Agent’s Office; Certain Addresses for Notices |
| 12 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE dated as of September 12, 2025 between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and THE BANK OF NEW YORK MELLON, a New York banking corporation, a... |
| 10 Sep 2025 |
8-K: Other Events
CAMBRIDGE, Mass. — September 9, 2025 — Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $575 million aggregate pr... |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
− Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – |
| 18 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
− R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics – |
| 13 May 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Alnylam Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”) does hereby certify: |
| 01 May 2025 |
8-K: Financial Statements and Exhibits
− Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – |
| 21 Mar 2025 |
8-K: Other Events
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) |
| 05 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
CAMBRIDGE, Mass., March 5, 2025 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, |
Loading...